CAT Studies

The following list contains a selection of the most recent clinical trials about cancer-associated thrombosis.

 

Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism: CASSINI Study

CASSINI study is an interventional, parallel study which purpose is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.

Click here for further details


 

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)

The AVERT study is an interventional, randomized, parallel study which aim is to test the safety and efficacy and assess the superiority of a new oral medication that has been used to prevent blood clots in high-risk cancer patients undergoing surgery.

Click here for further details. 


 

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients: SELECT-D Study

The SELECT-D Study is a interventional, randomized, parallel study which purpose is to show feasibility (efficacy and safety) of rivaroxaban in the treatment of VTE in patients with active cancer and newly diagnosed thromboembolic, in comparison to the standard treatment with low molecular weight heparin (LMWH).

Click here for further details.


 

A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism: PERIOP 2 Study

The PERIOP 2 Study is a prospective multicentre randomized double-blind controlled trial that intends to determine the effectiveness and safety of LMWH postoperative bridging therapy (standard of care) versus postoperative placebo bridging therapy (experimental arm)for patients with mechanical heart valves or atrial fibrillation or atrial flutter who are at high risk for stroke when warfarin is temporarily interrupted for a procedure.

Click here for further details.


 

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: CLOT Study

The study compared the efficacy of a low-molecular-weight heparin (dalteparine) with that of an oral anticoagulant agent (coumarin-derivative) in preventing recurrent thrombosis in patients with cancer.

Click here for further details.


 

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots: the Edoxaban Hokusai-VTE Study

The HOKUSAI-VTE Study is a randomized, double-blind, non-inferiority study that intends to assess whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism. Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.

Click here for further details.


Long-Term Innohep® (tinzaparin) Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

The CATCH study is a randomized, open label, parallel assignment study whose composite end-point is represented by the time in days from randomization to the first occurrence of VTE in patients with with a diagnosis of active cancer symptomatic and objectively confirmed VTE. The purpose of this study is to assess the efficacy and safety of tinzaparin in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.

Click here for further details

  1. Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. Thromb Haemost. 2018 May;118(5):914-921. doi: 10.1055/s-0038-1641150. Epub 2018 Apr 4.
  2. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015 Aug 18;314(7):677-686. doi: 10.1001/jama.2015.9243. Erratum in: JAMA. 2017 Nov 28;318(20):2048. Lee AY,
  3. Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, Khorana AA; CATCH Investigators. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer. 2013 Jun 13;13:284. doi: 10.1186/1471-2407-13-284.

Rate this article

Login or register to leave a comment or rate this article


Register